Key Points 1. The research evaluated prognostic factors and survival outcomes of patients who underwent surgery for high-grade neuroendocrine carcinoma of the cervix (NECC) through a multicenter ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Michael O’Donnell and Mario Fernandez join Peter Black to discuss the impact of variant histology on managing patients with bladder cancer. Carissa Chu joins Sam Chang to discuss data on genetic ...

Pembrolizumab is under clinical development by Merck and currently in Phase II for Anal Cancer. According to GlobalData, Phase II drugs for Anal Cancer have a 19% phase transition success rate (PTSR) ...

For example, Beljaards et al. (1987) argued that the histology of earlier reported cases were consistent with verrucous carcinoma, despite original authors' diagnosis of PKMB. Jenkins and ...

Gynecologic Oncology, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, China Background: Uterine carcinosarcoma (UCS), or malignant mixed Müllerian tumor, is a cancer that include ...

The following is a summary of “Epidermal spongiotic Langerhans cell collections, but not eosinophils, are a clue to the ...

Background: The impact that smoking cigarettes has on the characteristics and survival of patients with non-small cell lung cancer (NSCLC) is disputed. Methods: A retrospective cohort study using ...

A 73 year-old woman underwent a screening colonoscopy, which found a polypoid mass in the ascending colon. The mass was resected using a snare around the stalk.

Protocol was amended to incorporate a new updated search on March 2024. Twenty-five studies evaluating N4 positivity in GU tumors were included, 14 on UBC, three on upper tract urothelial carcinoma ...

The approval means that Libtayo is now the first immunotherapy approved in Europe to treat advanced cervical cancer, regardless of PD-L1 expression or tumour histology. The fourth leading cause of ...

Cilag’s Rybrevant in combo with Lazcluze for first-line treatment of patients with EGFR-mutated advanced NSCLC: Beerse, Belgium Tuesday, Dec ...